| scholarly article | Q13442814 |
| P50 | author | Florian Wrensch | Q55465237 |
| Mirjam Zeisel | Q73424648 | ||
| Thomas F Baumert | Q88786090 | ||
| P2093 | author name string | Catherine Schuster | |
| Emilie Crouchet | |||
| P2860 | cites work | Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly | Q24297412 |
| Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication | Q24302046 | ||
| Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 | Q24609988 | ||
| Review and management of drug interactions with boceprevir and telaprevir | Q24628716 | ||
| Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection | Q24646403 | ||
| microRNA-122 stimulates translation of hepatitis C virus RNA | Q24654912 | ||
| Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent | Q24656023 | ||
| Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection | Q26779128 | ||
| New drugs for treating dyslipidemia: beyond statins | Q26821840 | ||
| Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets | Q27468855 | ||
| Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles | Q27472884 | ||
| Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis | Q27473290 | ||
| Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins | Q27478188 | ||
| Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period | Q87439606 | ||
| Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment | Q87700511 | ||
| Effect of ezetimibe in HCV viral load after liver transplantation | Q95492399 | ||
| Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion | Q27485447 | ||
| Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B | Q27488369 | ||
| Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex | Q27488788 | ||
| Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics | Q27489037 | ||
| SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro | Q27490844 | ||
| Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
| Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes | Q27928046 | ||
| Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes | Q28081216 | ||
| The lipid droplet is an important organelle for hepatitis C virus production | Q28131709 | ||
| Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | Q28282776 | ||
| Treatment of HCV infection by targeting microRNA | Q29547712 | ||
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 | ||
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis | Q29620612 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids | Q29620653 | ||
| Hepatitis C virus infection | Q30235491 | ||
| Access to treatment for hepatitis C virus infection: time to put patients first | Q30248987 | ||
| A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication | Q33269990 | ||
| Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives | Q34045760 | ||
| Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha | Q34084372 | ||
| Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. | Q34194575 | ||
| Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor | Q34245963 | ||
| Profile of alisporivir and its potential in the treatment of hepatitis C. | Q34329744 | ||
| Hepatocyte nuclear factor 4α and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus | Q34381310 | ||
| Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents | Q34416004 | ||
| Global distribution and prevalence of hepatitis C virus genotypes | Q34431175 | ||
| Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients | Q34438448 | ||
| The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro | Q34504825 | ||
| Different anti-HCV profiles of statins and their potential for combination therapy with interferon | Q34541863 | ||
| Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking | Q34652154 | ||
| MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. | Q34721015 | ||
| Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin | Q34768265 | ||
| Fluvastatin inhibits hepatitis C replication in humans | Q34769764 | ||
| Hepatitis C virus life cycle and lipid metabolism | Q34792436 | ||
| Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation | Q34792600 | ||
| Virion assembly and release | Q38086754 | ||
| New hepatitis C therapies: the toolbox, strategies, and challenges | Q38196150 | ||
| Cyclophilin inhibition as potential therapy for liver diseases | Q38232505 | ||
| Hepatitis C virus RNA replication and assembly: living on the fat of the land | Q38294573 | ||
| The mechanism of HCV entry into host cells | Q38321419 | ||
| Treatment of hepatitis C in difficult-to-treat patients | Q38431523 | ||
| Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens | Q38808740 | ||
| Hepatitis C virus infection and chronic kidney disease: Time for reappraisal | Q38819960 | ||
| Prevention and management of treatment failure to new oral hepatitis C drugs. | Q38826624 | ||
| Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial | Q38839784 | ||
| Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients | Q38880996 | ||
| Hepatitis C virus resistance to the new direct-acting antivirals | Q38887954 | ||
| Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents | Q38893229 | ||
| SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection | Q38921779 | ||
| Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections | Q38951860 | ||
| Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis | Q38963481 | ||
| miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis | Q38979938 | ||
| Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection | Q38990715 | ||
| Cyclophilin inhibitors reduce phosphorylation of RNA-dependent protein kinase to restore expression of IFN-stimulated genes in HCV-infected cells | Q38999757 | ||
| Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. | Q39118328 | ||
| Current therapy for chronic hepatitis C: The role of direct-acting antivirals | Q39151677 | ||
| Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. | Q39154271 | ||
| Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release | Q39617748 | ||
| Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors | Q39646696 | ||
| Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. | Q39798599 | ||
| Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo | Q39912694 | ||
| Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape | Q40271516 | ||
| Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver | Q40392671 | ||
| Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. | Q40463023 | ||
| A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. | Q40479352 | ||
| Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes | Q40622941 | ||
| New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). | Q40747582 | ||
| A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. | Q40888934 | ||
| Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection | Q40907444 | ||
| Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study | Q40957442 | ||
| Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. | Q41064083 | ||
| Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients | Q41508623 | ||
| Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. | Q41603967 | ||
| The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes | Q41843629 | ||
| Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development | Q42168234 | ||
| In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. | Q42181792 | ||
| The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. | Q42211503 | ||
| ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. | Q42219325 | ||
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3. | Q42220605 | ||
| ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis | Q42225140 | ||
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 | ||
| Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 | ||
| Curing chronic hepatitis C--the arc of a medical triumph | Q42225548 | ||
| Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1 | Q42321933 | ||
| Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein | Q42983822 | ||
| Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period | Q42985156 | ||
| An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. | Q42986911 | ||
| HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. | Q42990165 | ||
| Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy | Q42997897 | ||
| Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin | Q43000770 | ||
| Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial | Q43036828 | ||
| The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. | Q43046668 | ||
| Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle | Q43254780 | ||
| Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C | Q43991768 | ||
| Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. | Q44847210 | ||
| Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy | Q45376579 | ||
| Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia | Q46573174 | ||
| Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. | Q50555912 | ||
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
| Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome | Q34795106 | ||
| Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection | Q34995301 | ||
| Effects of statins on the risk of hepatocellular carcinoma | Q34997752 | ||
| Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. | Q35135565 | ||
| Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin | Q35270890 | ||
| Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. | Q35399890 | ||
| All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study | Q35538245 | ||
| Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody | Q35602284 | ||
| Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma | Q35619104 | ||
| AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets | Q35641039 | ||
| Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals | Q35694689 | ||
| The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action | Q35742761 | ||
| Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. | Q35828072 | ||
| Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis | Q35995534 | ||
| MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis | Q36129123 | ||
| Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. | Q36129129 | ||
| Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection | Q36142772 | ||
| Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. | Q36233117 | ||
| Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals | Q36306768 | ||
| PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice | Q36330881 | ||
| Statins and cancer prevention | Q36337970 | ||
| Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation | Q36990362 | ||
| New perspectives for preventing hepatitis C virus liver graft infection | Q37015805 | ||
| Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection | Q37029846 | ||
| Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems | Q37148014 | ||
| Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C | Q37304715 | ||
| Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). | Q37349005 | ||
| Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study | Q37582317 | ||
| EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy | Q37609988 | ||
| Host-targeting agents in the treatment of hepatitis C: a beginning and an end? | Q37676364 | ||
| Hepatitis C virus evasion mechanisms from neutralizing antibodies | Q37967737 | ||
| SKI-1/S1P inhibition: a promising surrogate to statins to block hepatitis C virus replication | Q38012896 | ||
| Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis | Q38051955 | ||
| Hepatitis C virus entry | Q38086750 | ||
| Hepatitis C virus RNA translation | Q38086752 | ||
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 1756284818759483 | |
| P577 | publication date | 2018-03-21 | |
| P1433 | published in | Therapeutic Advances in Gastroenterology | Q21042423 |
| P1476 | title | Host-targeting therapies for hepatitis C virus infection: current developments and future applications | |
| P478 | volume | 11 |
| Q96126330 | A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor |
| Q104486634 | Characterization of the erythrocyte GTPase Rac1 in relation to Plasmodium falciparum invasion |
| Q90825369 | Dengue drug discovery: Progress, challenges and outlook |
| Q90643079 | Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis |
| Q61805220 | Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets |
| Q57813384 | Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges |
Search more.